Европейский союз - хорватский - EMA (European Medicines Agency)

eli lilly and company limited  - mcloksikam - mišićno-koštani sustav - psi - ublažavanje upale i boli kod akutnih i kroničnih poremećaja mišića i kostiju.

Европейский союз - хорватский - EMA (European Medicines Agency)

eli lilly and company limited  - fentanil - Živčani sustav - psi - za kontrolu boli povezane s ortopedskim i kirurgija mekih tkiva kod pasa.

Европейский союз - хорватский - EMA (European Medicines Agency)

eli lilly and company limited - korištenje, милбемициноксима - Противопаразитарные sredstva, insekticidi i repelenti endectocides - psi - za liječenje i prevenciju buha (ctenocephalides feliz) infestacije kod pasa, gdje je jedan ili više od sljedećih simptoma potrebno je istovremeno: prevencija srčanog crva bolesti (Л3, Л4 srčani crvi);prevencija angiostrongylosis smanjivanjem razine infekcije nezrele odrasle osobe (Л5) angiostrongylus vasorum;liječenje crijevnih hookworms infekcija uzrokovanih hookworms (Л4, nezreo odrasla osoba, Л5) i odrasle ancylostoma сатпит), oblići (nezreo odrasla osoba l5 i odrasle Тохосага canis i toxascaris leonina ograničen odrasla osoba) i власоглава (odrasli власоглавы vulpis).

Европейский союз - хорватский - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Европейский союз - хорватский - EMA (European Medicines Agency)

eli lilly nederland b.v. - olaratumab - sarkom - antineoplastična sredstva - lartruvo je indiciran u kombinaciji s doksorubicinom za liječenje odraslih bolesnika s uznapredovalim sarkomom mekih tkiva koji su podvrgnuti liječenju uz operaciju ili radioterapiju i koji nisu bili prethodno tretirani s doksorubicinom (vidjeti odjeljak 5.

Европейский союз - хорватский - EMA (European Medicines Agency)

eli lilly nederland b.v. - inzulin lispro - Šećerna bolest - lijekovi koji se koriste u dijabetesu - za liječenje odraslih i djece s dijabetesom koji zahtijevaju inzulin za održavanje normalne homeostaze glukoze. liprolog je također indiciran za početnu stabilizaciju šećerne bolesti.

Европейский союз - хорватский - EMA (European Medicines Agency)

janssen-cilag international nv - danmavir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Европейский союз - хорватский - EMA (European Medicines Agency)

eli lilly nederland b.v. - olanzapin - schizophrenia; bipolar disorder - psycholeptics - obložena tabletsadultsolanzapine indiciran za liječenje shizofrenije. Оланзапин učinkovit u održavanju kliničkog poboljšanja u roku od nastavka terapije kod pacijenata koji su pokazali odgovor na liječenje . Оланзапин je indiciran za liječenje umjerene do teških maničnih epizoda. kod pacijenata epizoda kojega je manično reagirao na liječenje Оланзапин, Оланзапин je indiciran za prevenciju relapsa kod pacijenata s bipolarnim poremećajem. injectionadultszyprexa prašak za pripremu otopine za injekcije indiciran za brzo upravljanje uznemirenosti i poremećaja oblika ponašanja kod bolesnika shizofrenije ili manične epizode, kada je usmeni terapija ne odgovara. treba prekinuti liječenje Зипрекса prašak za pripremu otopine za injekcije i korištenje oralne Оланзапин treba početi čim se klinički.

Европейский союз - хорватский - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant se može koristiti kao monoterapija ili u kombinaciji s metotreksatom. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Европейский союз - хорватский - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplazme dojki - antineoplastična sredstva - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.